December 21, 2020 08:20 AM EST
R&D

Fol­low­ing a quick ap­proval in AML, Astel­las' Xospa­ta flops in chemo com­bo for front­line pa­tients

Nicole DeFeudis

Editor

Two years af­ter land­ing a fast OK in acute myeloid leukemia, Astel­las Phar­ma’s FLT3 in­hibitor Xospa­ta flunked a Phase III tri­al as­sess­ing its abil­i­ty to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times